• Bacteria medical illustration

    TAXIS Pharmaceuticals Announces Publication of Preclinical Data on Investigational Efflux Pump Inhibitor TXA11114 in journal Antibiotics

    Miami, FL – May 12, 2026 — TAXIS Pharmaceuticals, a clinical-stage company developing investigational anti-resistance therapies to address antimicrobial resistance (AMR), today announced the publication of preclinical data in the peer-reviewed journal Antibiotics describing TXA11114, an investigational indole carboxamide efflux pump inhibitor (EPI) designed to [...]

  • Cision PR Web Logo

    TAXIS Pharmaceuticals Names Angela Fonceca, PhD to Its Australian Board of Directors

    February 10, 2026 — TAXIS Pharmaceuticals Australia Pty Ltd has named Angela Fonceca, PhD, an industry professional with extensive biopharma experience, to its Board of Directors. TAXIS Pharmaceuticals, a clinical-stage company focused on developing investigational therapies to combat multidrug-resistant bacterial infections and address antimicrobial resistance [...]

  • Bacteria outbreak and bacterial infection as a microscopic background

    TAXIS Pharmaceuticals Responds to CDC Report on Surge in Antibiotic-Resistant Bacteria

    September 25, 2025 — TAXIS Pharmaceuticals today issued a statement in response to a new report from the Centers for Disease Control and Prevention (CDC), published in the Annals of Internal Medicine on September 23. The CDC report highlights a dramatic increase in infections caused [...]

  • Joeseph DePinto, MBA, and Frank Carlo Pasqualone, MBA

    Joe DePinto, MBA and Frank Carlo Pasqualone, MBA Named to Board of Directors

    TAXIS Pharmaceuticals has named two industry professionals with extensive biopharma experience, Joeseph DePinto, MBA, and Frank Carlo Pasqualone, MBA, to its Board of Directors.

  • lab tech looking at petri dish

    $2.9 Million NIH Grant for Novel Investigational Therapeutic to Combat Antibiotic-Resistant Gonorrhea

    TAXIS has received a $2.9 million grant to further advance R&D efforts for its dihydrofolate reductase inhibitors (DHFRIs) as a novel approach to combat multi-drug resistant gonorrhea, a rapidly spreading deadly and highly resistant strain of Neisseria gonorrhoeae.

  • House Budget Committee Roundtable – Threat of Antibiotic Resistance

    On July 25, House Budget Committee bipartisan roundtable entitled, “Threats to Modern Medicine: Examining the Budgetary Effects of Antimicrobial Resistance (AMR) and the Broken Antibiotic Development Pipeline.”

  • TAXIS Pharmaceuticals Announces $2.67 Million NIH Grant

    TAXIS Pharmaceuticals Announces $2.67 Million NIH Grant to Advance Research and Development of Combination Therapy to Combat Antibiotic-Resistant Pneumonia. Originally published in NORTH BRUNSWICK, N.J., May 1, 2024 /PRNewswire-PRWeb/

  • TAXIS Pharmaceuticals Publishes on FtzS Inhibitors in the Journal of Antibiotics

    FtsZ inhibitors represent a new drug class as no drugs using this mode of action (MOA) have been approved by regulators. In this paper, we present the screening and evaluation of a benzamide class that is functionalized at the alkoxy fragment targeting Gram-negative bacteria.

  • TAXIS Publishes on Efflux Pump Inhibitors in MDPI Journal Antibiotics

    Efflux pumps in Gram-negative bacteria such as Pseudomonas aeruginosa provide intrinsic antimicrobial resistance by facilitating the extrusion of a wide range of antimicrobials. Approaches for combating efflux-mediated multidrug resistance involve, in part, developing indirect antimicrobial agents capable of inhibiting efflux, thus rescuing the activity of antimicrobials previously rendered inactive by efflux. Herein, TXA09155 is presented as a novel efflux pump inhibitor (EPI) formed by conformationally constraining our previously reported EPI TXA01182. TXA09155 demonstrates strong potentiation in combination with multiple antibiotics with efflux liabilities against wild-type and multidrug-resistant (MDR) P. aeruginosa.